T.H. v. Novartis Pharmaceuticals Corp.
California Supreme Court
407 P.3d 18, 4 Cal.5th 145, 226 Cal.Rptr.3d 336 (2017)
- Written by Rose VanHofwegen, JD
Facts
Novartis Pharmaceuticals Corp. (defendant) manufactured a brand-name drug called Brethine that was prescribed to pregnant women experiencing preterm labor. T.H. and C.H. (plaintiffs) were exposed to the generic version, terbutaline, in utero. The children sued, alleging that the warning label failed to warn about fetal brain development risks and misrepresented the drug as safe for pregnant women. Novartis moved to dismiss, arguing it had no duty to maintain or update the warning label because it stopped making Brethine and sold all rights to it six years earlier and never made the generic version. The trial court granted dismissal, but the appellate court reversed. Novartis appealed.
Rule of Law
Issue
Holding and Reasoning (Cuéllar, J.)
What to do next…
Here's why 803,000 law students have relied on our case briefs:
- Written by law professors and practitioners, not other law students. 46,300 briefs, keyed to 988 casebooks. Top-notch customer support.
- The right amount of information, includes the facts, issues, rule of law, holding and reasoning, and any concurrences and dissents.
- Access in your classes, works on your mobile and tablet. Massive library of related video lessons and high quality multiple-choice questions.
- Easy to use, uniform format for every case brief. Written in plain English, not in legalese. Our briefs summarize and simplify; they don’t just repeat the court’s language.